Pathstone Holdings
ARQT icon

Pathstone Holdings’s Arcutis Biotherapeutics ARQT Stock Holding History

Pathstone Holdings’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,523
Closed -$243K – 2197
2025
Q1 		$243K Buy
+15,523
New +$219K ﹤0.01% 2002

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Pathstone Holdings's ARQT Position: Q2 2025 in Review

Pathstone Holdings sold out of Arcutis Biotherapeutics (ARQT) in Q2 2025, closing a stake of 15,523 shares — an estimated $243K sold.

Pathstone Holdings first reported a position in ARQT in Q1 2025 and held it in 1 quarter. The position peaked at $243K in Q1 2025. 230 funds tracked by Wall St. Rank hold ARQT as of Q2 2025.

  • Pathstone Holdings reported no remaining Arcutis Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Pathstone Holdings sold 15,523 Arcutis Biotherapeutics shares in Q2 2025, an estimated $243K.
  • Pathstone Holdings first reported a position in Arcutis Biotherapeutics in Q1 2025 and held it in 1 quarter.
  • Pathstone Holdings's Arcutis Biotherapeutics position peaked at $243K in Q1 2025.
  • 230 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2025.

Based on Pathstone Holdings's 13F filing for Q2 2025, filed 12 Aug 2025.